Cartesian Therapeutics, Inc. Income Tax Examination, Penalties and Interest Expense
Cartesian Therapeutics, Inc. (RNAC) reported Income Tax Examination, Penalties and Interest Expense of $1.30 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-03-07.
Discontinued › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2024-03-07
- Cartesian Therapeutics, Inc. income tax examination, penalties and interest expense for fiscal 2021 was $1.30M.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2021-12-31 | $1.30M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |